Cargando…

The efficacy of the anthracycline prodrug daunorubicin-GA3 in human ovarian cancer xenografts.

The prodrug N-[4-(daunorubicin-N-carbonyl-oxymethyl)phenyl] O-beta-glucuronyl carbamate (DNR-GA3) was synthesized for specific activation by human beta-glucuronidase, released in necrotic areas of tumour lesions. In vitro, DNR-GA3 was 18 times less toxic than daunorubicin (DNR) and the prodrug was c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Houba, P. H., Boven, E., Erkelens, C. A., Leenders, R. G., Scheeren, J. W., Pinedo, H. M., Haisma, H. J.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group\|1 1998
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063245/ https://www.ncbi.nlm.nih.gov/pubmed/9862570

Ejemplares similares

A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer
por: Houba, P H J, et al.
Publicado: (2001)

The anti-tumour effects of the prodrugs N-l-leucyl-doxorubicin and vinblastine-isoleucinate in human ovarian cancer xenografts.
por: Boven, E., et al.
Publicado: (1992)

Comparison of monoclonal antibodies 17-1A and 323/A3: the influence of the affinity on tumour uptake and efficacy of radioimmunotherapy in human ovarian cancer xenografts.
por: Kievit, E., et al.
Publicado: (1996)

A monoclonal antibody-beta-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer.
por: Haisma, H. J., et al.
Publicado: (1992)

Activity of GR30921X (NSC 382057) and GR63178A (NSC D611615) in human ovarian cancer lines.
por: Boven, E., et al.
Publicado: (1990)

Enhanced transplantability of human ovarian cancer lines in cyclophosphamide-pretreated nude mice.
por: Nauta, M. M., et al.
Publicado: (1986)

The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer.
por: Boven, E., et al.
Publicado: (1993)

A fully human anti-Ep-CAM scFv-beta-glucuronidase fusion protein for selective chemotherapy with a glucuronide prodrug
por: de Graaf, M, et al.
Publicado: (2002)

Drug resistance features and S-phase fraction as possible determinants for drug response in a panel of human ovarian cancer xenografts
por: Kolfschoten, G M, et al.
Publicado: (2000)

Characterization of human soft-tissue sarcoma xenografts for use in secondary drug screening.
por: Boven, E., et al.
Publicado: (1998)

Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts
por: Patil, Satish, et al.
Publicado: (2015)

Increased plasma membrane traffic in daunorubicin resistant P388 leukaemic cells. Effect of daunorubicin and verapamil.
por: Sehested, M., et al.
Publicado: (1987)

Synthesis and antitumor efficacy of daunorubicin-loaded magnetic nanoparticles
por: Wang, Jun, et al.
Publicado: (2011)

Novel Polyhedral Silsesquioxanes [POSS(OH)(32)] as Anthracycline Nanocarriers—Potential Anticancer Prodrugs
por: Piorecka, Kinga, et al.
Publicado: (2020)

Enhancing the Therapeutic Efficacy of Daunorubicin and Mitoxantrone with Bavachinin, Candidone, and Tephrosin
por: Darzi, Sina, et al.
Publicado: (2019)

Effect of anthracycline analogs on photolabelling of p-glycoprotein by [125I]iodomycin and [3H]azidopine: relation to lipophilicity and inhibition of daunorubicin transport in multidrug resistant cells.
por: Friche, E., et al.
Publicado: (1993)

Adipocyte metabolism of the chemotherapy daunorubicin
por: Mittelman, Steven D., et al.
Publicado: (2018)

Predicting Response to Anthracyclines in Ovarian Cancer
por: Ferrero, Annamaria, et al.
Publicado: (2022)

Reversal of multidrug resistance by magnetic Fe(3)O(4) nanoparticle copolymerizating daunorubicin and 5-bromotetrandrine in xenograft nude-mice
por: Chen, Baoan, et al.
Publicado: (2009)

Liposomal daunorubicin as treatment for Kaposi’s sarcoma
por: Petre, Christin E, et al.
Publicado: (2007)

Interactions of Cisplatin and Daunorubicin at the Chromatin Level
por: Firouzi Niaki, Erfaneh, et al.
Publicado: (2020)

Ovarian tumour xenografts in the study of the biology of human epithelial ovarian cancer.
por: Friedlander, M. L., et al.
Publicado: (1985)

Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience
por: Tefferi, Ayalew, et al.
Publicado: (2022)

Targeting hypoxic microenvironment of pancreatic xenografts with the hypoxia-activated prodrug TH-302
por: Lohse, Ines, et al.
Publicado: (2016)

Albumin nanoparticles increase the anticancer efficacy of albendazole in ovarian cancer xenograft model
por: Noorani, Lubna, et al.
Publicado: (2015)

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
por: Lancet, Jeffrey E., et al.
Publicado: (2018)

Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer
por: Sun, Jessica D, et al.
Publicado: (2015)

Orthotopic xenografts of human melanoma and colonic and ovarian carcinoma in sheep to evaluate radioimmunotherapy.
por: Turner, J. H., et al.
Publicado: (1998)

CAM-Xenograft Model Provides Preclinical Evidence for the Applicability of [(68)Ga]Ga-Pentixafor in CRC Imaging
por: Benčurová, Katarína, et al.
Publicado: (2022)

The induction of apoptosis by daunorubicin and idarubicin in human trisomic and diabetic fibroblasts
por: Dragojew, Sylwia, et al.
Publicado: (2008)

MR Imaging Biomarkers to Monitor Early Response to Hypoxia-Activated Prodrug TH-302 in Pancreatic Cancer Xenografts
por: Zhang, Xiaomeng, et al.
Publicado: (2016)

Comparison of the pharmacokinetics, biodistribution and dosimetry of monoclonal antibodies OC125, OV-TL 3, and 139H2 as IgG and F(ab')2 fragments in experimental ovarian cancer.
por: Molthoff, C. F., et al.
Publicado: (1992)

Acquired resistance to daunorubicin in a patient with acute myelogenous leukaemia.
por: Smith, B. J., et al.
Publicado: (1976)

P-glycoprotein expression in Ehrlich ascites tumour cells after in vitro and in vivo selection with daunorubicin.
por: Nielsen, D., et al.
Publicado: (1998)

Metabolic Efficacy of Phosphate Prodrugs and the Remdesivir Paradigm
por: Wiemer, Andrew J.
Publicado: (2020)

Dead or alive? The manipulation of neuronal ensembles and pathways by daunorubicin
por: Bashir, Zafar Iqbal, et al.
Publicado: (2017)

Author Correction: Interactions of Cisplatin and Daunorubicin at the Chromatin Level
por: Firouzi Niaki, Erfaneh, et al.
Publicado: (2020)

Role of Drug Metabolism in the Cytotoxicity and Clinical Efficacy of Anthracyclines
por: Edwardson, Derek W., et al.
Publicado: (2015)

Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase IIβ inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity
por: Bavlovič Piskáčková, Hana, et al.
Publicado: (2021)

Daunorubicin pharmacokinetics and the correlation with P-glycoprotein and response in patients with acute leukaemia.
por: Galettis, P., et al.
Publicado: (1994)

Cannot write session to /tmp/vufind_sessions/sess_s7992m6k4odoirl918jjvaphq4